NAFDAC to continue hydroxychloroquine clinical trials for treatment of COVID-19 in Nigeria despite suspension

The National Agency for Food and Drug Administration and Control says it will continue hydroxychloroquine clinical trials for the treatment of COVID-19 in Nigeria despite the suspension of the same by the World Health Organisation.

NAFDAC Director-General, Prof Mojisola Adeyeye, made this known on Tuesday during a programme on Television Continental monitored by Punch Newspaper.

Adeyeye said there are proven records that hydroxychloroquine had been effective in the treatment of COVID-19 patients, especially those at the “mild stage” of the virus.

“There is data to prove that hydroxychloroquine worked for many COVID-19 patients. Therefore, we would continue our own clinical trials in Nigeria. Hydroxychloroquine has been proved to work at a mild stage. So the potency depends on the severity of the disease in the patient’s body,” she said.

The NAFDAC DG, who said Lagos State had already begun hydroxychloroquine clinical trials, noted that depending on the speed of work, the clinical trials should conclude in three to four months.

“If medical doctors, research scientists, pharmacists, herbal experts work together, we should conclude the clinical trial in three to four months. The narrative might change afterwards but for now, we believe in hydroxychloroquine.”

To continue telling under-reported stories, we need your support for the work we do, donate to https://www.paystack.com/paynewswirengr

Also, kindly donate to the work we do using this interim PAYPAL ID https://www.paypal.me/NewsWireNGR